Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Glenmark Life Scienc
Join Channel
Consolidated Standalone

Glenmark Life Scienc

₹827 -7.8 | 0.9%

Market Cap ₹10133 Cr.

Stock P/E 21.5

P/B 4.3

Current Price ₹827

Book Value ₹ 190.4

Face Value 2

52W High ₹904.2

Dividend Yield 2.72%

52W Low ₹ 512.7

Edit Ratio

Glenmark Life Scienc Research see more...

Overview Inc. Year: 2011Industry: Pharmaceuticals & Drugs

Glenmark Life Sciences Ltd develops, manufactures, and supplies non-commoditized active pharmaceutical components for various chronic therapeutic regions in India. The organization offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system sicknesses; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain control. It also offers Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other healing areas. In addition, the enterprise offers contract development and manufacturing services to more than a few multinational pharmaceutical and distinctiveness pharmaceutical corporations. It additionally exports its merchandise to Europe, North America, Latin America, Japan, and the world over. The organization incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Ltd is a subsidiary of Glenmark Pharmaceuticals Ltd.

Read More..

Glenmark Life Scienc Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Glenmark Life Scienc Quarterly Results

#(Fig in Cr.) Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 522 514 490 509 541 621 578 595 573 537
Other Income 4 5 9 10 7 3 2 5 2 3
Total Income 526 519 499 519 547 624 580 601 574 540
Total Expenditure 376 372 343 366 395 415 385 428 400 395
Operating Profit 150 147 156 154 152 209 195 172 174 145
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 10 10 10 10 11 12 13 13 13 15
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 140 138 146 144 141 198 182 159 161 130
Provision for Tax 36 39 38 37 36 51 47 40 42 32
Profit After Tax 104 99 109 107 105 146 135 119 119 98
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 104 99 109 107 105 146 135 119 119 98
Adjusted Earnings Per Share 8.5 8.1 8.9 8.7 8.6 11.9 11.1 9.7 9.7 8

Glenmark Life Scienc Profit & Loss

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 0 886 1537 1885 2123 2161 2283
Other Income 0 1 12 1 15 29 12
Total Income 0 887 1549 1886 2138 2190 2295
Total Expenditure 0 639 1065 1294 1507 1519 1608
Operating Profit -0 248 484 592 631 671 686
Interest 0 1 34 88 28 1 0
Depreciation 0 19 29 33 38 42 54
Exceptional Income / Expenses 0 0 0 0 0 0 0
Profit Before Tax -0 228 421 471 565 629 632
Provision for Tax 0 33 108 119 146 162 161
Profit After Tax -0 196 313 352 419 467 471
Adjustments 0 0 0 0 0 0 0
Profit After Adjustments -0 196 313 352 419 467 471
Adjusted Earnings Per Share -7.9 18.1 29 32.6 34.2 38.1 38.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 2% 12% 0% 0%
Operating Profit CAGR 6% 12% 0% 0%
PAT CAGR 11% 14% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 58% NA% NA% NA%
ROE Average 22% 38% 138% 115%
ROCE Average 30% 56% 176% 147%

Glenmark Life Scienc Balance Sheet

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds -1 88 402 753 2054 2138
Minority's Interest 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0
Other Non-Current Liabilities 0 7 16 23 33 60
Total Current Liabilities 1 1380 1307 1445 747 1023
Total Liabilities 0 1475 1726 2221 2834 3220
Fixed Assets 0 456 546 573 590 781
Other Non-Current Assets 0 88 19 25 117 71
Total Current Assets 0 931 1160 1623 2127 2369
Total Assets 0 1475 1726 2221 2834 3220

Glenmark Life Scienc Cash Flow

#(Fig in Cr.) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 0 0 2 10 116 512
Cash Flow from Operating Activities -0 10 195 388 598 313
Cash Flow from Investing Activities 0 -9 -51 -69 -122 -154
Cash Flow from Financing Activities 0 1 -137 -214 -79 -388
Net Cash Inflow / Outflow 0 2 8 106 397 -228
Closing Cash & Cash Equivalent 0 2 10 116 512 284

Glenmark Life Scienc Ratios

# Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) -7.89 18.14 29.04 32.61 34.17 38.11
CEPS(Rs) -7.89 19.93 31.77 35.71 37.27 41.55
DPS(Rs) 0 0 0 0 21 21
Book NAV/Share(Rs) -25.42 8.17 37.26 69.83 167.38 173.97
Core EBITDA Margin(%) -5.24 27.88 30.66 31.28 28.98 29.56
EBIT Margin(%) -5.24 25.82 29.53 29.55 27.89 28.96
Pre Tax Margin(%) -5.24 25.75 27.35 24.92 26.58 28.93
PAT Margin (%) -175 22.07 20.34 18.6 19.7 21.49
Cash Profit Margin (%) -175 24.24 22.25 20.37 21.48 23.43
ROA(%) -510.59 26.51 19.56 17.82 16.57 15.43
ROE(%) 0 451.05 127.84 60.91 29.87 22.33
ROCE(%) 0 527.74 185.6 96.75 42.24 30.01
Receivable days 45.63 92.26 128.84 121.5 111.01 124.34
Inventory Days 55.93 82.54 96.46 89.45 88.4 94.11
Payable days 56.49 100.55 105.53 87.85 94.72 130.6
PER(x) 0 0 0 0 13.43 10.28
Price/Book(x) 0 0 0 0 2.74 2.25
Dividend Yield(%) 0 0 0 0 4.58 5.36
EV/Net Sales(x) 0.01 -0 -0.01 -0.06 2.41 2.08
EV/Core EBITDA(x) -0.23 -0 -0.02 -0.19 8.1 6.69
Net Sales Growth(%) 0 0 73.43 22.63 12.63 1.79
EBIT Growth(%) 0 0 98.59 22.86 6.16 6.12
PAT Growth(%) 0 0 60.08 12.29 19.1 11.52
EPS Growth(%) 0 329.94 60.08 12.29 4.78 11.52
Debt/Equity(x) 0 0 0 0 0 0
Current Ratio(x) 0.06 0.67 0.89 1.12 2.85 2.32
Quick Ratio(x) 0.03 0.38 0.57 0.77 2.16 1.73
Interest Cover(x) 0 378.35 13.56 6.38 21.2 1150.19
Total Debt/Mcap(x) 0 0 0 0 0 0

Glenmark Life Scienc Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 82.85 82.85 82.85 82.85 82.85 82.85 82.85 82.85 82.85 82.85
FII 8.32 8.12 7.58 6.03 4.46 3.29 3.27 4.38 4.57 5.01
DII 0.47 0.56 0.79 0.81 0.09 0 0.58 0.64 0.74 1.4
Public 8.36 8.47 8.78 10.31 12.6 13.86 13.3 12.12 11.84 10.73
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 38%
  • Company is almost debt free.

Cons

  • Debtor days have increased from 94.72 to 130.6days.
  • Stock is trading at 4.3 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Glenmark Life Scienc News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!